Tandem Diabetes Care Inc. experienced a significant after-hours decline of 5.84% on Monday. The drop followed the regular trading session where the stock had closed with substantial gains.

The sharp decline is attributed to the company's announcement of a proposed private placement of $200 million in convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $30 million. Convertible offerings often lead to stock price pressure due to concerns about potential dilution when the notes are converted into shares and the increased debt burden on the company's balance sheet.

Tandem Diabetes Care plans to use the net proceeds from the offering for general corporate purposes, which may include acquisitions, strategic investments, working capital, and operating expenses. The company also intends to use a portion of the proceeds to pay for capped call transactions, which are derivative instruments designed to help offset potential dilution from the conversion of the notes.